RPID

Rapid Micro Biosystems (RPID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

White Brook Capital’s Q3 2026 investor letter expresses cautious optimism. Its Ethical All-Cap Strategy has outperformed, while the Small Cap Strategy has lagged because of execution delays, higher interest rates, and market pressure.

LEXINGTON, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc.

Rapid Micro Biosystems (RPID) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

The heavy selling pressure might have exhausted for Rapid Micro Biosystems (RPID) as it is technically in oversold territory now.

Record gross margins and 200th system milestone signal momentum toward profitability.

Rapid Micro Biosystems (RPID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Moby summary of Rapid Micro Biosystems, Inc.'s Q2 2026 earnings call

Company exceeds Q2 guidance with 11% revenue growth and record gross margin, while reaffirming full-year outlook and advancing key partnerships.

Rapid Micro Biosystems (NASDAQ:RPID) reported second-quarter revenue of $8.1 million, up 11% from $7.3 million a year earlier and above the company’s prior guidance, as consumable sales, service activity and recurring revenue increased.

Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -3.85% and +3.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?